Literature DB >> 20815376

Primary tumor xenografts of human lung adeno and squamous cell carcinoma express distinct proteomic signatures.

Yuhong Wei1, Jiefei Tong, Paul Taylor, Dan Strumpf, Vladimir Ignatchenko, Nhu-An Pham, Naoki Yanagawa, Geoffrey Liu, Igor Jurisica, Frances A Shepherd, Ming-Sound Tsao, Thomas Kislinger, Michael F Moran.   

Abstract

Nonsmall cell lung carcinoma (NSCLC) accounts for 80% of lung cancers. The most prevalent subtypes of NSCLC are adenocarcinoma (ADC) and squamous cell carcinoma (SCC), which combined account for approximately 90%. Ten resected NSCLC patient tumors (5 ADC and 5 SCC) were directly introduced into severely immune deficient (NOD-SCID) mice, and the resulting xenograft tumors were analyzed by standard histology and immunohistochemistry (IHC) and by proteomics profiling. Mass spectrometry (MS) methods involving 1- and 2-dimensional LC-MS/MS, and multiplexed selective reaction monitoring (SRM, or MRM), were applied to identify and quantify the xenograft proteomes. Hierarchical clustering of protein profiles distinguished between the ADC and SCC subtypes. The differential expression of 178 proteins, including a comprehensive panel of intermediate filament keratin proteins, was found to constitute a distinctive proteomic signature associated with the NSCLC subtypes. Epidermal growth factor receptor (EGFR) was expressed in ADC and SCC xenografts, and EGFR network activation was assessed by phosphotyrosine profiling by Western blot analysis and SRM measurement of EGFR levels, and mutation analysis. A multiplexed SRM/MRM method provided relative quantification of several keratin proteins, EGFR and plakophilin-1 in single LC-MS/MS runs. The protein quantifications by SRM and MS/MS spectral counting were associated with superior dynamic range and reproducibility but were otherwise consistent with orthogonal methods including IHC and Western immuno blotting. These findings illustrate the potential to develop a comprehensive MS-based platform in oncologic pathology for better classification and potentially treatment of NSCLC patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20815376     DOI: 10.1021/pr100491e

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   4.466


  12 in total

1.  Relative protein quantification and accessible biology in lung tumor proteomes from four LC-MS/MS discovery platforms.

Authors:  Paul A Stewart; Bin Fang; Robbert J C Slebos; Guolin Zhang; Adam L Borne; Katherine Fellows; Jamie K Teer; Y Ann Chen; Eric Welsh; Steven A Eschrich; Eric B Haura; John M Koomen
Journal:  Proteomics       Date:  2017-03       Impact factor: 3.984

2.  Reliable Entity Subtyping in Non-small Cell Lung Cancer by Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry on Formalin-fixed Paraffin-embedded Tissue Specimens.

Authors:  Mark Kriegsmann; Rita Casadonte; Jörg Kriegsmann; Hendrik Dienemann; Peter Schirmacher; Jan Hendrik Kobarg; Kristina Schwamborn; Albrecht Stenzinger; Arne Warth; Wilko Weichert
Journal:  Mol Cell Proteomics       Date:  2016-07-29       Impact factor: 5.911

3.  Integrated analysis of proteome, phosphotyrosine-proteome, tyrosine-kinome, and tyrosine-phosphatome in acute myeloid leukemia.

Authors:  Jiefei Tong; Mohamed Helmy; Florence M G Cavalli; Lily Jin; Jonathan St-Germain; Robert Karisch; Paul Taylor; Mark D Minden; Michael D Taylor; Benjamin G Neel; Gary D Bader; Michael F Moran
Journal:  Proteomics       Date:  2017-03       Impact factor: 3.984

4.  Managing a Large-Scale Multiomics Project: A Team Science Case Study in Proteogenomics.

Authors:  Paul A Stewart; Eric A Welsh; Bin Fang; Victoria Izumi; Tania Mesa; Chaomei Zhang; Sean Yoder; Guolin Zhang; Ling Cen; Fredrik Pettersson; Yonghong Zhang; Zhihua Chen; Chia-Ho Cheng; Ram Thapa; Zachary Thompson; Melissa Avedon; Marek Wloch; Michelle Fournier; Katherine M Fellows; Jewel M Francis; James J Saller; Theresa A Boyle; Y Ann Chen; Eric B Haura; Jamie K Teer; Steven A Eschrich; John M Koomen
Journal:  Methods Mol Biol       Date:  2021

5.  Selected Reaction Monitoring (SRM) Analysis of Epidermal Growth Factor Receptor (EGFR) in Formalin Fixed Tumor Tissue.

Authors:  Todd Hembrough; Sheeno Thyparambil; Wei-Li Liao; Marlene M Darfler; Joseph Abdo; Kathleen M Bengali; Paul Taylor; Jiefei Tong; Humberto Lara-Guerra; Thomas K Waddell; Michael F Moran; Ming-Sound Tsao; David B Krizman; Jon Burrows
Journal:  Clin Proteomics       Date:  2012-05-03       Impact factor: 3.988

Review 6.  Integrative computational biology for cancer research.

Authors:  Kristen Fortney; Igor Jurisica
Journal:  Hum Genet       Date:  2011-04-22       Impact factor: 4.132

Review 7.  Novel approaches for the identification of biomarkers of aggressive prostate cancer.

Authors:  Yunee Kim; Thomas Kislinger
Journal:  Genome Med       Date:  2013-06-28       Impact factor: 11.117

8.  Quantitative proteomic analysis of human lung tumor xenografts treated with the ectopic ATP synthase inhibitor citreoviridin.

Authors:  Yi-Hsuan Wu; Chia-Wei Hu; Chih-Wei Chien; Yu-Ju Chen; Hsuan-Cheng Huang; Hsueh-Fen Juan
Journal:  PLoS One       Date:  2013-08-21       Impact factor: 3.240

9.  Enhancing the utility of Proteomics Signature Profiling (PSP) with Pathway Derived Subnets (PDSs), performance analysis and specialised ontologies.

Authors:  Wilson Wen Bin Goh; Mengyuan Fan; Hong Sang Low; Marek Sergot; Limsoon Wong
Journal:  BMC Genomics       Date:  2013-01-16       Impact factor: 3.969

10.  A Pilot Proteogenomic Study with Data Integration Identifies MCT1 and GLUT1 as Prognostic Markers in Lung Adenocarcinoma.

Authors:  Paul A Stewart; Katja Parapatics; Eric A Welsh; André C Müller; Haoyun Cao; Bin Fang; John M Koomen; Steven A Eschrich; Keiryn L Bennett; Eric B Haura
Journal:  PLoS One       Date:  2015-11-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.